Skip to main content

Aligos Therapeutics, Inc.

ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001799448

No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Holders of 5% or more of ALGS

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aligos Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ALGS
HolderLatest formStakeChangeFirst filedLatest filingFiling
Alyeska Investment Group, L.P.13G9.99%530.0K sharesNewMay 15, 20251 filingMay 15, 2025SEC
Blatt Lawrence13D5.60%316.2K shares+0.50 ppfrom 5.10%Feb 11, 20216 filingsJun 24, 2026SEC
Sio Capital Management, LLC13G/A5.46%335.9K shares−0.03 ppfrom 5.49%Aug 13, 20252 filingsFeb 11, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

41 Schedule 13D and 13G filings on Aligos Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ALGS
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jun 24, 20264:30 PM ETBlatt Lawrence13D5.60%316.2K shares+0.50 ppfrom 5.10%Jun 16, 2026SEC
May 15, 20264:30 PM ETBlatt Lawrence13G5.10%286.2K shares+1.90 ppfrom 3.20%Mar 31, 2026SEC
May 15, 20269:05 AM ETWoodline Partners LP13G/A4.40%239.4K shares−1.00 ppfrom 5.40%Below 5%Mar 31, 2026SEC
Feb 17, 20263:22 PM ETWoodline Partners LP13G/A5.40%289.2K shares−3.30 ppfrom 8.70%Dec 31, 2025SEC
Feb 11, 20264:32 PM ETSio Capital Management, LLC13G/A5.46%335.9K shares−0.03 ppfrom 5.49%Dec 31, 2025SEC
Nov 14, 20254:15 PM ETWoodline Partners LP13G/A8.70%468.2K shares−1.10 ppfrom 9.80%Sep 30, 2025SEC
Aug 14, 202511:54 AM ETWoodline Partners LP13G/A9.80%518.3K shares+4.60 ppfrom 5.20%Jun 30, 2025SEC
Aug 13, 20252:00 PM ETSio Capital Management, LLC13G5.49%355.9K sharesNewJun 30, 2025SEC
Aug 12, 20259:00 AM ETAdage Capital Management, L.P.and 2 others13G/A3.90%210.0K shares−5.48 ppfrom 9.38%Below 5%Jun 30, 2025SEC
May 15, 20254:20 PM ETAlyeska Investment Group, L.P.and 2 others13G9.99%530.0K sharesNewMar 31, 2025SEC
May 15, 20251:53 PM ETEcoR1 Capital, LLCand 2 others13G/A3.90%210.6K shares–Below 5%Mar 31, 2025SEC
May 15, 20259:33 AM ETWoodline Partners LP13G5.20%315.4K sharesNewMar 31, 2025SEC
Mar 12, 20258:30 PM ETBlatt Lawrence13D/A3.20%175.5K shares–Below 5%Mar 10, 2025SEC
Feb 14, 20254:56 PM ETArmistice Capital, LLCand 1 other13G/A4.99%188.4K shares–Below 5%Dec 31, 2024SEC
Feb 12, 20259:32 AM ETAdage Capital Management, L.P.and 2 others13G/A9.38%325.0K shares–Dec 31, 2024SEC
Feb 14, 2023Tang Capital Partners LP13G/AOld format–––SEC
Feb 14, 2023HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse)13G/AOld format–––SEC
Feb 13, 2023EcoR1 Capital, LLC13G/AOld format–––SEC
Feb 9, 2023Janus Henderson Group PLC13G/AOld format–––SEC
Feb 8, 2023Blatt Lawrence13G/AOld format–––SEC
Dec 27, 2022Tang Capital Partners LP13GOld format–New–SEC
Feb 14, 2022Janus Henderson Group PLC13GOld format–New–SEC
Feb 14, 2022Baker Bros. Advisors LP13GOld format–New–SEC
Feb 14, 2022EcoR1 Capital, LLC13GOld format–New–SEC
Feb 14, 2022Logos Global Management LP13G/AOld format–––SEC
Feb 14, 2022HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse)13G/AOld format–––SEC
Feb 10, 2022Beigelman Leonid13G/AOld format–––SEC
Feb 10, 2022Blatt Lawrence13G/AOld format–––SEC
Feb 10, 2022Wellington Management Group LLP13G/AOld format–––SEC
Feb 4, 2022Wellington Management Group LLP13G/AOld format–––SEC
Feb 4, 2022Wellington Biomedical Innovation Master Investors (Cayman) I L.P.13G/AOld format–––SEC
Jan 31, 2022Novo Holdings A/S13D/AOld format–––SEC
Aug 13, 2021Logos Global Management LP13GOld format–New–SEC
Jun 21, 2021Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Jun 21, 2021Novo Holdings A/S13D/AOld format–––SEC
May 3, 2021Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Feb 16, 2021Roche Finance Ltd13GOld format–New–SEC
Feb 16, 2021HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse)13GOld format–New–SEC
Feb 11, 2021Blatt Lawrence13GOld format–New–SEC
Feb 11, 2021Beigelman Leonid13GOld format–New–SEC
Jan 11, 2021Wellington Management Group LLP13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Aligos Therapeutics, Inc. shares.

No Form 144 notices for Aligos Therapeutics, Inc. are on file.